30 hasil untuk "Jenner, Peter"
Menampilkan 1–20 · 0,73 detik · RSS
-
Artikel Jurnal Teks lengkap
Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future
The problems associated with the pharmacological treatment of the later stages of Parkinson’s disease (PD) remain those seen over many years. These centre on a loss of drug effect (‘wearing off’) with disease progression, the occurrence of dyskinesia, notably with L-dopa use and the appearance of…
-
Artikel Jurnal Teks lengkap
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease
Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of novel treatments for motor symptoms of PD and in the search for clues to the underlying cause of the illness. Models based on specific pathogenic mechanisms may subsequently lead to the development of…
-
Artikel Jurnal Teks lengkap
COMT inhibition with entacapone for patients with Parkinson’s disease and motor complications: the novelty of continuous infusion
Enhancing levodopa efficacy through peripheral COMT inhibition and using continuous infusion are both established strategies for managing motor fluctuations. Both approaches aim to improve the pharmacokinetics of levodopa in order to maintain a steady delivery of levodopa to the brain, avoid the…
-
Artikel Jurnal Teks lengkap
Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson’s disease
In levodopa treated patients with Parkinson’s disease (PD), the standard approach to managing motor fluctuations is to adjust dopaminergic therapy. However, despite the availability of a wide armamentarium of dopaminergic medications, most patients treated with levodopa will still experience…
-
Artikel Jurnal Teks lengkap
The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates
1. Endogenous L-DOPA may act as a neuromodulator contributing to the production of motor activity. We now investigate the effects of the centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor NSD-1015 (3-hydroxybenzyl hydrazine) on the motor actions of L-DOPA and dopamine agonist…
-
Artikel Jurnal Teks lengkap
Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected
Non-motor symptoms are a key component of Parkinson's disease, possibly representing a clinical biomarker of its premotor phase. The burden of non-motor symptoms can define a patient's health-related quality of life. Non-motor symptoms substantially increase the cost of care—requiring increased…
-
Artikel Jurnal Teks lengkap
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson’s disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the…
-
Artikel Jurnal Teks lengkap
Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint
To date, there are no clinically effective neuroprotective or disease-modifying treatments that can halt Parkinson's disease (PD) progression. The current clinical approach focuses on symptomatic management. This failure may relate to the complex neurobiology underpinning the development of PD and…
-
Artikel Jurnal Teks lengkap
Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors
Apomorphine is the only dopamine agonist used to treat Parkinson disease with similar efficacy to levodopa. Its original characterization as a dopamine agonist was based on its receptor binding profile and capacity to recruit G proteins; however, current knowledge of G protein-coupled receptors…
-
Artikel Jurnal Teks lengkap
Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson’s Disease
The symptomatic treatment of Parkinson’s disease (PD) has been dominated by the use of dopaminergic medication, but significant unmet need remains, much of which is related to non-motor symptoms and the involvement of non-dopaminergic transmitter systems. As such, little has changed in the past…
-
Artikel Jurnal Teks lengkap
3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates
Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] was shown to prolong the action of l-3,4-dihydroxyphenylalanine (l-DOPA) while suppressing dyskinesia in a single patient with Parkinson's disease (PD). The clinical basis of this effect of MDMA is unknown but may relate to its actions on either…
-
Artikel Jurnal Teks lengkap
The Pharmacological Potential of Adenosine A(2A) Receptor Antagonists for Treating Parkinson’s Disease
The adenosine A(2A) receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson’s disease (PD). The selective A(2A) receptor antagonist istradefylline is approved in the US and Japan as an adjunctive treatment to…
-
Artikel Jurnal Teks lengkap
Changes in gene expression in macrophages infected with Mycobacterium tuberculosis: a combined transcriptomic and proteomic approach
We investigated the changes which occur in gene expression in the human macrophage cell line, THP1, at 1, 6 and 12 hr following infection with Mycobacterium tuberculosis. The analysis was carried out at the transcriptome level, using microarrays consisting of 375 human genes generally thought to be…
-
Artikel Jurnal Teks lengkap
Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
Dysfunction of the gastrointestinal tract has now been recognized to affect all stages of Parkinson’s disease (PD). The consequences lead to problems with absorption of oral medication, erratic treatment response, as well as silent aspiration, which is one of the key risk factors in developing…
-
Artikel Jurnal Teks lengkap
Expression of a Gene for a Porin-Like Protein of the OmpA Family from Mycobacterium tuberculosis H37Rv
An open reading frame in the genomic database of Mycobacterium tuberculosis H37Rv was identified as having homology with an outer membrane protein. We found that the gene specified a protein belonging to the OmpA family, which includes some porins of gram-negative organisms. The gene was amplified…